Avalo Therapeutics Inc (AVTX) — Cash Flow-to-Debt Ratio
Avalo Therapeutics Inc (AVTX) has a Cash Flow-to-Debt Ratio of -0.49x as of September 2025, meaning its operating cash flow of $-16.36 Million could theoretically repay 0% of its total liabilities ($33.55 Million) in one year. Check Avalo Therapeutics Inc (AVTX) reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Avalo Therapeutics Inc Cash Flow-to-Debt Ratio (2012–2024)
Historical debt coverage capacity for Avalo Therapeutics Inc across 13 annual periods. Also explore AVTX total assets for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for Avalo Therapeutics Inc (2012–2024)
Year-by-year debt coverage analysis for Avalo Therapeutics Inc. For market capitalisation and broader financial context, see AVTX market cap.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -2.77x | $-49.06 Million | $17.70 Million | ▼ -23.7% |
| 2023 | -2.24x | $-30.68 Million | $13.69 Million | ▼ -271.0% |
| 2022 | -0.60x | $-26.75 Million | $44.28 Million | ▲ +51.3% |
| 2021 | -1.24x | $-70.89 Million | $57.13 Million | ▲ +41.3% |
| 2020 | -2.11x | $-40.54 Million | $19.19 Million | ▼ -66.8% |
| 2019 | -1.27x | $-19.13 Million | $15.11 Million | ▼ -1897.1% |
| 2018 | -0.06x | $-3.13 Million | $49.34 Million | ▼ -107.7% |
| 2017 | 0.82x | $12.52 Million | $15.26 Million | ▲ +131.3% |
| 2016 | -2.62x | $-14.57 Million | $5.56 Million | ▼ -121.0% |
| 2015 | -1.19x | $-10.16 Million | $8.57 Million | ▼ -195.2% |
| 2014 | -0.40x | $-15.52 Million | $38.65 Million | ▲ +19.9% |
| 2013 | -0.50x | $-11.49 Million | $22.92 Million | ▲ +91.7% |
| 2012 | -6.02x | $-9.29 Million | $1.54 Million | — |